论文部分内容阅读
目的为探讨安博维(伊贝沙坦)、洛丁新(苯拉普利)联合治疗糖尿病肾病高血压的临床疗效。方法采用安博维(伊贝沙坦)150mg/d,洛丁新(苯拉普利)10～20mg/d,联用治疗糖尿病肾病高血压50例观察患者的血压、血糖控制情况。结果使用安博维(伊贝沙坦)、洛丁新(苯拉普利)联合治疗糖尿病肾病高血压能有效地控制患者的血压水平,达到目标值130/80mmHg,而且能保护患者的肾功能,避免发展为终末期肾病。结论使用安博维(伊贝沙坦)、洛丁新(苯拉普利)治疗糖尿病肾病高血压能保护患者的肾功能,使血压控制达到满意的水平,同时使患者空腹血糖及餐后2h血糖控制良好,对延缓终末期肾病有非常重大的意义。
Objective To investigate the clinical efficacy of Ambbevir (irbesartan) and luodingxin (trilaprost) in the treatment of hypertension with diabetic nephropathy. Methods 150 mg / day of irbesartan and 10 ~ 20 mg / day of losartin (melazepril) were used in combination with 50 cases of diabetic nephropathy to observe the blood pressure and blood glucose control. Results The combination of Ambbevir (irbesartan) and losartin (melazepril) in the treatment of diabetic nephropathy can effectively control the blood pressure of patients with the target value of 130 / 80mmHg, and can protect the patient’s renal function, Avoid the development of end-stage renal disease. Conclusions AMBE (irbesartan) and lobutin (TXL) in the treatment of diabetic nephropathy can protect the renal function of patients and achieve satisfactory blood pressure control. At the same time, patients’ fasting blood glucose and postprandial 2h blood glucose Good control, the delay of end-stage renal disease has a very significant significance.